Lianshan Zhang

USPTO Granted Patents = 9 (Patent Applications = 3)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 3.5

ph-index = 5

Forward Citations = 180(Granted Patents)

Location History:

Carmel, IN (US) (2006 - 2015)
Princeton Junction, NJ (US) (2015)
West Windsor, NJ (US) (2015)

Company Filing History:

7 out of 4,447

Eli Lilly and Company

patents

1 out of 11

Impact Therapeutics, Inc.

Marcadia Biotech, Inc.

patents

where one patent can have more than one assignee

Years Active: 2006-2015

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9145451 - Glucagon superfamily peptides exhbiting G protein coupled receptor activity (2015-09-29),

2. 9090568 - Quinazolinediones and their use (2015-07-28),

3. 9050371 - PEGylated insulin lispro compounds (2015-06-09),

4. 8183340 - GLP-1 pegylated compounds (2012-05-22),

5. 7897573 - Selective VPAC2 receptor peptide agonists (2011-03-01),

6. 7582608 - Selective VPAC2 receptor peptide agonists (2009-09-01),

7. 7557183 - Polyethylene glycol linked GLP-1 compounds (2009-07-07),

8. 7482321 - Extended glucagon-like peptide-1 analogs (2009-01-27),

9. 7101843 - Glucagon-like peptide-1 analogs (2006-09-05),

Title: Lianshan Zhang: Innovator in Pharmaceutical Sciences

Introduction

Lianshan Zhang is a prominent inventor based in Carmel, IN (US), known for his significant contributions to pharmaceutical sciences. With a total of 9 patents, he has made remarkable advancements in the field, particularly in the development of therapeutic compounds.

Latest Patents

Among his latest patents, Zhang has developed glucagon superfamily peptides exhibiting G protein-coupled receptor activity. These peptides are conjugated with GPCR ligands, enabling them to act effectively at G protein-coupled receptors. The invention also includes pharmaceutical compositions and kits containing these conjugates, along with methods for treating diseases such as metabolic disorders, diabetes, and obesity. Another notable patent involves quinazolinediones, which are compounds that inhibit poly(ADP-ribose) polymerases (PARP). This invention is crucial for treating various diseases and disorders related to PARP, and it includes pharmaceutical compositions and methods for utilizing these compounds.

Career Highlights

Lianshan Zhang has worked with esteemed companies such as Eli Lilly and Company and Impact Therapeutics, Inc. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Throughout his career, Zhang has collaborated with notable professionals, including Wolfgang Glaesner and Rohn Lee Millican, Jr. These partnerships have further enhanced his innovative work and expanded the impact of his inventions.

Conclusion

Lianshan Zhang's contributions to pharmaceutical sciences through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to influence the development of new therapeutic solutions for various health conditions.

This text is generated by artificial intelligence and may not be accurate.